Viatar CTC Solutions Reports Third Quarter 2015 Highlights and Financial Results

LOWELL, MA--(Marketwired - Nov 13, 2015) - Viatar CTC Solutions, Inc. (OTCQB: VRTT), a medical technology company focused on the treatment of patients with metastatic cancer, today announced highlights and financial results for the third quarter ended September 30, 2015.

• Generated $37,940 of revenue over the past four quarters from sales of Viatar's proprietary filters to a strategic collaborator, for use in that company's liquid biopsy device for molecular analysis.
• Received the prestigious Cavendish Global Health Innovation Award at the Cavendish Global Health Impact Forum co-hosted by Cleveland Clinic in October 2015.

For the third quarter of 2015, Viatar reported sales of $13,985 compared to no sales in the comparable quarter of 2014. For the first nine months of 2015, Viatar reported sales of $37,940 compared to $9,000 for the first nine months of 2014. Earlier this year, those sales were connected to evaluation testing of the Company's filters, but in the third quarter the Company's filters were integrated into a customer's product line for use by medical researchers at prominent cancer institutions.

Research & development expenses during the third quarter of 2015 were $677,878 compared to $552,321 in the third quarter of 2014. General and administrative expenses during the third quarter of 2015 were $250,648 compared to $136,031 in the third quarter of 2014. Expense increases reflect the ongoing development of the Company's two products based on its proprietary CTC removal technology as well as the required costs associated with being a public company.

Viatar reported a net loss of $934,784 for the third quarter of 2015 compared to a net loss of $706,015 for the comparable period in 2014. These losses include $160,266 and $346,379, respectively, of non-cash expenses for stock-based compensation.

For the nine months ended September 30, 2015 Viatar reported a net loss of $2,880,124, which included $857,515 of non-cash expenses for stock-based compensation.

At September 30, 2015, Viatar had cash assets of $107,432. In October 2015, the Company received $1.3 million in exchange for 4% convertible promissory notes due July 2018.

"Viatar's profile has begun to rise with our selection for the respected Cavendish Global Health Innovation Award and through our participation in investment conferences and ongoing investor meetings," said Ilan Reich, Chairman and CEO of Viatar CTC Solutions. "We also continue to meet our timetable for achieving CE Mark regulatory approval for Europe and Canada in late-2016, after which we can begin commercialization. A parallel effort is also underway to obtain FDA approval, but that will take several years due to the vastly different regulatory requirements."

Additional information can be found in the Company's Form 10Q for the period ended September 30, 2015.

About Viatar CTC Solutions

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells from whole blood using label-free cross-flow filtration. Pending regulatory approval targeted for 2016, it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers.

This proprietary technology also powers the company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.   

Viatar CTC Solutions Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(Unaudited)
			For the Nine Months Ended September 30,								For the Three Months Ended September 30,
			2015				2014				2015				2014
REVENUE
	Sales		$	37,940			$	9,000			$	13,985			$	-
COST OF REVENUE
	Cost of sales			7,660				-				3,830				-
GROSS MARGIN				30,280				9,000				10,155				-
EXPENSES
	Research and development			1,889,156				982,450				677,878				552,321
	General and administrative			948,116				806,176				250,648				136,031
TOTAL EXPENSES				2,837,272				1,788,626				928,526				688,352
LOSS FROM OPERATIONS				(2,806,992	)			(1,779,626	)			(918,371	)			(688,352	)
OTHER INCOME (EXPENSE)
	Change in value of derivative liability			-				1,800				-				-
	Interest expense			(73,132	)			(17,663	)			(16,413	)			(17,663	)
TOTAL OTHER INCOME (EXPENSE)				(73,132	)			(15,863	)			(16,413	)			(17,663	)
LOSS BEFORE INCOME TAX (EXPENSE) BENEFIT				(2,880,124	)			(1,795,489	)			(934,784	)			(706,015	)
	Income tax (expense) benefit			-				-				-				-
NET LOSS				(2,880,124	)			(1,795,489	)			(934,784	)			(706,015	)
	Net loss attributable to noncontrolling interest in consolidated subsidiary			(393	)			(280	)			(120	)			(194	)
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS			$	(2,879,731	)		$	(1,795,209	)		$	(934,664	)		$	(705,821	)
LOSS PER COMMON SHARE - BASIC AND DILUTED:
	Net Loss Attributable to Common Stockholders		$	(0.16	)		$	(0.12	)		$	(0.05	)		$	(0.04	)
	Weighted Average Shares			17,604,366				15,556,312				17,981,054				15,918,177

Viatar CTC Solutions Inc. and Subsidiary
Condensed Consolidated Balance Sheets
					September 30, 2015				December 31, 2014
					(Unaudited)
ASSETS
CURRENT ASSETS
	Cash				$	107,432			$	31,351
			TOTAL ASSETS		$	107,432			$	31,351
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
	Accounts payable and accrued expenses				$	190,595			$	290,210
	Accrued income tax liability					762,637				732,550
	Demand note payable					-				50,000
	Convertible note payable					-				93,495
		Total current liabilities				953,232				1,166,255
	Convertible note payable, net					400,000				-
			TOTAL LIABILITIES			1,353,232				1,166,255
	Commitments and contingencies
STOCKHOLDERS' DEFICIT
	Series A preferred stock, $.001 par value, 20,000,000 shares authorized, 4,000,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively					4,000				4,000
	Common stock, $.001 par value, 100,000,000 shares authorized, 18,107,176 and 16,814,426 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively					18,108				16,815
	Common stock subscription and interest receivable					-				(605,475	)
	Additional paid-in capital					19,773,834				17,611,374
	Accumulated deficit					(21,031,520	)			(18,151,789	)
			Total stockholders' deficit			(1,235,578	)			(1,125,075	)
	Noncontrolling interest					(10,222	)			(9,829	)
			TOTAL STOCKHOLDERS' DEFICIT			(1,245,800	)			(1,134,904	)
			TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$	107,432			$	31,351